References
- Tugal-Tutkun I, Urgancioglu M. Bilateral acute depigmentation of the iris. Graefes Arch Clin Exp Ophthalmol. 2006;244:742–746. doi:10.1007/s00417-005-0137-x.
- Tugal-Tutkun I, Araz B, Taskapili B, et al. Bilateral acute depigmentation of the iris: report of 26 new cases and four year follow-up of two patients. Ophthalmology. 2009;116:1552–1557. doi:10.1016/j.ophtha.2009.02.019.
- Singh S, Diwan S, Sachdev MS. Bilateral acute depigmentation of the iris in a child following exposure to insecticide spray. Indian J Ophthalmol. 2020;68:1191–1193. doi:10.4103/ijo.IJO_1676_19.
- Choi W, Kang HG, Choi EY, et al. Clinical utility of aqueous humor polymerase chain reaction and serologic testing for suspected infectious uveitis: a single-center retrospective study in South Korea. BMC Ophthalmol. 2020;20:242. doi:10.1186/s12886-020-01513-x.
- Sen M, Honavar SG, Sharma N, Sachdev MS. COVID-19 and eye: a review of ophthalmic manifestations of COVID-19. Indian J Ophthalmol. 2021;69:488–509. doi:10.4103/ijo.IJO_297_21.
- Tohamy D, Sharaf M, Abdelazeem K, et al. Ocular manifestations of post-acute COVID-19 syndrome, Upper Egypt early report. J Multidiscip Healthc. 2021;14:1935–1944. doi:10.2147/JMDH.S323582. Published 2021 Jul 23.
- Yagci BA, Atas F, Kaya M, Arikan GCOVID-19. Associated bilateral acute iris transillumination. Ocul Immunol Inflamm. 2021 May 19;29(4):719–721. doi:10.1080/09273948.2021.1933073.
- Tugal-Tutkun I, Onal S, Garip A, et al. Bilateral acute iris transillumination. Arch Ophthalmol. 2011;129(10):1312–1319. doi:10.1001/archophthalmol.2011.310.
- Knape R, Sayyad F, Davis J. Moxifloxacin and bilateral acute iris transillumination. J Ophthalmic Inflamm Infect. 2013;3(1):10. doi:10.1186/1869-5760-3-10.
- Nascimento H, Sousa J, Campos M, Belfort R Jr. Acute iris depigmentation following systemic moxifloxacin. Clinics. 2013;68(7):899–900. doi:10.6061/clinics/2013(07)02.
- Kawali A, Mahendradas P, Shetty R. Acutedepigmentationofthe iris: a retrospective analysis of 22 cases. Can J Ophthalmol. 2019;54:33–39. doi:10.1016/j.jcjo.2018.03.020.